PT-002 - DEVELOPMENTAL PHARMACOKINETICS AND PHARMACOGENOMICS OF ISONIAZID IN PREDOMINANTLY LOW-BIRTH-WEIGHT OR PRETERM INFANTS WITH OR WITHOUT HIV EXPOSURE.

A. Béranger¹, A. Bekker², B. Pérez Solans¹, M. Cotton², M. Mirochnick³, A. Violari⁴, M. Cababasay⁵, J. Wang⁵, L. Wiesner⁶, R. Browning⁷, J. Moye⁸, E. Capparelli⁹, R. Savic¹; ¹University of California San Francisco, San Francisco, CA, USA, ²Stellenbosch University and Tygerberg Hospital, Cape Town, South Africa, ³Boston University School of Medicine, Boston, MA, USA, ⁴University of the Witwatersrand, Johannesburg, South Africa, ⁵Harvard T.H. Chan School of Public Heath, Boston, MA, USA, ⁶University of Cape Town, Cape Town, South Africa, ⁷National Institute of Allergy and Infectious Diseases, Bethesda, MD, USA, ⁸National Institutes of Health, Bethesda, MD, USA, ⁹University of California San Diego, La Jolla, CA, USA.